Trial Profile
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Ficlatuzumab (Primary) ; Cetuximab
- Indications Carcinoma; Head and neck cancer; Nasopharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 28 Mar 2023 Results published in the Journal of Clinical Oncology
- 08 Sep 2022 Status changed from active, no longer recruiting to completed.
- 07 Mar 2022 Planned End Date changed from 31 Dec 2021 to 30 May 2022.